The micro invasive glaucoma surgery (MIGS) devices market is projected to register a substantial CAGR of 33.3% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.
Market Segmentation:
Global Micro Invasive Glaucoma Surgery (MIGS) Devices Market, By Product (MIGS Stents, MIGS Shunts and Others), Target (Trabecular Meshwork Suprachoroidal Space Subconjunctival Filtration and Reducing Aqueous Production), Surgery Type (Glaucoma in Conjunction with Cataract and Stand-Alone Glaucoma), End User (Hospital Outpatient Departments (HOPD), Ophthalmology Clinics, Ambulatory Surgery Centers (ASCS) and Others), Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and rest of Asia-Pacific, Brazil, Argentina and rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and rest of Middle East and Africa) - Industry Trends & Forecast to 2029
Some of the major factors contributing to the growth of the global micro invasive glaucoma surgery (MIGS) devices market are:
Increase in the geriatric population
Rising incidence of glaucoma across the world
Government initiatives to increase awareness about prevention of blindness
Market Players:
The key market players for the micro invasive glaucoma surgery (MIGS) devices market are listed below:
AbbVie
BVI
Ellex
Glaukos Corporation
Johnson and Johnson
Alcon
Microsurgical technology
New World Medical
Santen Pharmaceutical
Nova Eye Medical Limited
Belkin Vision
Sight Scientific
TABLE OF CONTENTS
1 INTRODUCTION 23
- 1.1 OBJECTIVES OF THE STUDY 23
- 1.2 MARKET DEFINITION 23
- 1.3 OVERVIEW OF GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET 23
- 1.4 LIMITATIONS 24
- 1.5 MARKETS COVERED 24
2 MARKET SEGMENTATION 27
- 2.1 MARKETS COVERED 27
- 2.2 GEOGRAPHICAL SCOPE 28
- 2.3 YEARS CONSIDERED FOR THE STUDY 29
- 2.4 CURRENCY AND PRICING 29
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
- 2.6 MULTIVARIATE MODELLING 33
- 2.7 PRODUCTS LIFELINE CURVE 33
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
- 2.9 DBMR MARKET POSITION GRID 35
- 2.10 MARKET APPLICATION COVERAGE GRID 36
- 2.11 VENDOR SHARE ANALYSIS 37
- 2.12 SECONDARY SOURCES 38
- 2.13 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 42
- 4.1 INTERNATIONAL STANDARDS 42
- 4.2 REGIONAL STANDARDS 42
- 4.3 MARKET VIEWPOINT OF KEY OPINION LEADERS 42
- 4.4 EXPECTATIONS OF FUTURE MARKET SCENARIOS 42
- 4.5 FINDINGS AND REGIONAL TRENDS 43
- 4.6 COMPETITIVE GROUPING 44
5 COUNTRY WISE- NO OF PROCEDURES 54
- 5.1 NORTH AMERICA 55
- 5.2 EUROPE 56
- 5.3 ASIA-PACIFIC 57
- 5.4 SOUTH AMERICA 58
- 5.5 MIDDLE EAST AND AFRICA 59
6 REGULATION 60
- 6.1 UNITED STATES 60
- 6.2 EUROPE 61
- 6.3 CHINA 62
- 6.4 AUSTRALIA 62
7 MARKET OVERVIEW 64
- 7.1 DRIVERS 66
- 7.1.1 INCREASE IN THE GERIATRIC POPULATION 66
- 7.1.2 RISE IN INCIDENCE OF GLAUCOMA ACROSS THE WORLD 66
- 7.1.3 GOVERNMENT INITIATIVES TO INCREASE AWARENESS ABOUT THE PREVENTION OF BLINDNESS 67
- 7.1.4 GROWTH IN POPULARITY OF MINIMALLY INVASIVE SURGERY ACROSS THE GLOBE 67
- 7.2 RESTRAINTS 68
- 7.2.1 INADEQUATE REIMBURSEMENT SCENARIO 68
- 7.2.2 STRINGENT REGULATIONS FOR MIGS DEVICES 68
- 7.2.3 HIGH COST OF SURGICAL PROCEDURES 68
- 7.3 OPPORTUNITIES 69
- 7.3.1 RAPID TRANSITION FROM GLAUCOMA MEDICATION TO MINIMALLY INVASIVE GLAUCOMA SURGERIES 69
- 7.3.2 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCT 69
- 7.4 CHALLENGES 70
- 7.4.1 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE 70
- 7.4.2 RISKS ASSOCIATED WITH THE MICRO INVASIVE GLAUCOMA SURGERY 71
8 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY PRODUCT 72
- 8.1 OVERVIEW 73
- 8.2 MIGS STENTS 76
- 8.3 MIGS SHUNTS 76
- 8.4 OTHERS 77
9 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY TARGET 78
- 9.1 OVERVIEW 79
- 9.2 TRABECULAR MESHWORK 82
- 9.3 SUPRACHOROIDAL SPACE 82
- 9.4 SUBCONJUNCTIVAL FILTRATION 83
- 9.5 REDUCING AQUEOUS PRODUCTION 84
10 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY SURGERY TYPE 85
- 10.1 OVERVIEW 86
- 10.2 GLAUCOMA IN CONJUNCTION WITH CATARACT 89
- 10.3 STAND-ALONE GLAUCOMA 89
11 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY END USER 91
- 11.1 OVERVIEW 92
- 11.2 HOSPITAL 95
- 11.3 OPHTHALMOLOGY CLINICS 95
- 11.4 AMBULATORY SURGERY CENTERS (ASCS) 96
- 11.5 OTHERS 97
12 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY DISTRIBUTION CHANNEL 98
- 12.1 OVERVIEW 99
- 12.2 DIRECT TENDER 102
- 12.3 RETAIL SALES 102
13 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY REGION 104
- 13.1 OVERVIEW 105
- 13.2 NORTH AMERICA 110
- 13.2.1 U.S. 116
- 13.2.2 CANADA 118
- 13.2.3 MEXICO 120
- 13.3 EUROPE 122
- 13.3.1 GERMANY 128
- 13.3.2 FRANCE 130
- 13.3.3 U.K. 132
- 13.3.4 ITALY 134
- 13.3.5 SPAIN 136
- 13.3.6 SWITZERLAND 138
- 13.3.7 NETHERLANDS 140
- 13.3.8 BELGIUM 142
- 13.3.9 RUSSIA 144
- 13.3.10 TURKEY 146
- 13.3.11 REST OF EUROPE 148
- 13.4 ASIA-PACIFIC 149
- 13.4.1 CHINA 155
- 13.4.2 JAPAN 157
- 13.4.3 INDIA 159
- 13.4.4 SOUTH KOREA 161
- 13.4.5 AUSTRALIA 163
- 13.4.6 SINGAPORE 165
- 13.4.7 THAILAND 167
- 13.4.8 MALAYSIA 169
- 13.4.9 INDONESIA 171
- 13.4.10 PHILIPPINES 173
- 13.4.11 REST OF ASIA-PACIFIC 175
- 13.5 SOUTH AMERICA 176
- 13.5.1 BRAZIL 182
- 13.5.2 ARGENTINA 184
- 13.5.3 REST OF SOUTH AMERICA 186
- 13.6 MIDDLE EAST AND AFRICA 187
- 13.6.1 SOUTH AFRICA 193
- 13.6.2 SAUDI ARABIA 195
- 13.6.3 U.A.E. 197
- 13.6.4 ISRAEL 199
- 13.6.5 EGYPT 201
- 13.6.6 REST OF MIDDLE EAST AND AFRICA 203
14 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET: COMPANY LANDSCAPE 204
- 14.1 COMPANY SHARE ANALYSIS: GLOBAL 204
- 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 205
- 14.3 COMPANY SHARE ANALYSIS: EUROPE 206
- 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 207
15 SWOT ANALYSIS 208
16 COMPANY PROFILE 209
- 16.1 GLAUKOS CORPORATION 209
- 16.1.1 COMPANY SNAPSHOT 209
- 16.1.2 REVENUE ANALYSIS 209
- 16.1.3 COMPANY SHARE ANALYSIS 210
- 16.1.4 PRODUCT PORTFOLIO 210
- 16.1.4.1 RECENT DEVELOPMENT 210
- 16.2 ALCON INC. 211
- 16.2.1 COMPANY SNAPSHOT 211
- 16.2.2 REVENUE ANALYSIS 211
- 16.2.3 COMPANY SHARE ANALYSIS 212
- 16.2.4 PRODUCT PORTFOLIO 212
- 16.2.4.1 RECENT DEVELOPMENTS 213
- 16.3 ABBVIE INC. 214
- 16.3.1 COMPANY SNAPSHOT 214
- 16.3.2 REVENUE ANALYSIS 214
- 16.3.3 COMPANY SHARE ANALYSIS 215
- 16.3.4 PRODUCT PORTFOLIO 215
- 16.3.4.1 RECENT DEVELOPMENT 215
- 16.4 JOHNSON & JOHNSON SURGICAL VISION, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON) 216
- 16.4.1 COMPANY SNAPSHOT 216
- 16.4.2 REVENUE ANALYSIS 216
- 16.4.3 COMPANY SHARE ANALYSIS 217
- 16.4.4 PRODUCT PORTFOLIO 217
- 16.4.4.1 RECENT DEVELOPMENT 217
- 16.5 SANTEN PHARMACEUTICAL CO., LTD. 218
- 16.5.1 COMPANY SNAPSHOT 218
- 16.5.2 REVENUE ANALYSIS 218
- 16.5.3 COMPANY SHARE ANALYSIS 219
- 16.5.4 PRODUCT PORTFOLIO 219
- 16.5.4.1 RECENT DEVELOPMENTS 219
- 16.6 BELKIN VISION, ISRAEL 221
- 16.6.1 COMPANY SNAPSHOT 221
- 16.6.2 PRODUCT PORTFOLIO 221
- 16.6.3 RECENT DEVELOPMENT 221
- 16.7 BVI 222
- 16.7.1 COMPANY SNAPSHOT 222
- 16.7.2 PRODUCT PORTFOLIO 222
- 16.7.2.1 RECENT DEVELOPMENTS 223
- 16.8 ELLEX INC. 224
- 16.8.1 COMPANY SNAPSHOT 224
- 16.8.2 PRODUCT PORTFOLIO 224
- 16.8.2.1 RECENT DEVELOPMENTS 224
- 16.9 IOPTIMA 225
- 16.9.1 COMPANY SNAPSHOT 225
- 16.9.2 PRODUCT PORTFOLIO 225
- 16.9.3 RECENT DEVELOPMENT 225
- 16.10 MICROSURGICAL TECHNOLOGY. (A SUBSIDIARY OF HALMA PLC) 226
- 16.10.1 COMPANY SNAPSHOT 226
- 16.10.2 PRODUCT PORTFOLIO 226
- 16.10.2.1 RECENT DEVELOPMENT 226
- 16.11 NEW WORLD MEDICAL, INC. 227
- 16.11.1 COMPANY SNAPSHOT 227
- 16.11.2 PRODUCT PORTFOLIO 227
- 16.11.2.1 RECENT DEVELOPMENTS 227
- 16.12 NOVA EYE MEDICAL LIMITED 228
- 16.12.1 COMPANY SNAPSHOT 228
- 16.12.2 REVENUE ANALYSIS 228
- 16.12.3 PRODUCT PORTFOLIO 229
- 16.12.3.1 RECENT DEVELOPMENTS 229
- 16.13 SIGHT SCIENCES. 230
- 16.13.1 COMPANY SNAPSHOT 230
- 16.13.2 REVENUE ANALYSIS 230
- 16.13.3 PRODUCT PORTFOLIO 231
- 16.13.3.1 RECENT DEVELOPMENTS 231
17 QUESTIONNAIRE 233
18 RELATED REPORTS 235